Adjuvant therapy for breast cancer: Recommendations for management based on consensus review and recent clinical trials

Oncologist

Volumn 7, Issue 3, 2002, Pages 246-250

  Mincey, Betty A ^a   Palmieri, Frances M ^a   Perez, Edith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adjuvant therapy; Anthracyclines; Breast cancer; Taxanes

Indexed keywords

ANASTROZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; MONOCLONAL ANTIBODY; TAMOXIFEN;

BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; HUMAN; MULTIMODALITY CANCER THERAPY; ONCOGENE NEU; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; CONSENSUS DEVELOPMENT CONFERENCES; FEMALE; HUMANS; PATIENT CARE PLANNING; PROGNOSIS; RISK ASSESSMENT; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0036079608     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-3-246     Document Type: Review

References (15)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Tamoxifen for early breast cancer: An overview of the randomised trials
3. National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000
4. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
5. Adjuvant anti-HER monoclonal antibody therapy-ready for breast cancer?
6. HER-2 as a prognostic, predictive, and therapeutic target in breast cancer
7. When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer
8. The ATAC (arimidex, tamoxifen, alone or in combination) adjuvant breast cancer trail in postmenopausal (PM) women
9. Tamoxifen and chemotherapy for axillary node-negative, estrogen receptor-negative breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-23
10. CMF versus CAF with or without tamoxifen in high-risk node-negative breast cancer patients and a natural history follow up study in low-risk node-negative patients: Update of tamoxifen results
11. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent; initial results from intergroup trial 0100 (SWOG-8814)
12. Epirubicin-cyclophosphamide (EC) chemotherapy plus tamoxifen (T) administered concurrent (con) versus sequential (sec): Randomized phase III trial in postmenopausal node-positive breast cancer (BC) patients
13. Phase III trial comparing TAC (docetaxel, doxorubicin, cyclophosphamide) with FAC (5-fluorouracil, doxorubicin, cyclophosphamide) in the adjuvant treatment of node positive breast cancer (BC) patients: Interim analysis of the BCIRG001 study
14. Incorporation of taxanes in the adjuvant management of patients with breast cancer, incorporating data presented at the 2000 NIH Consensus Development Conference
15. Integration of trastuzumab into adjuvant systemic therapy of breast cancer: Ongoing and planned clinical trials